Diffuse large B-cell lymphoma trials in Hong Kong

3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Where

  Hong Kong

  Age

  18 years and over

  People

  1,046 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06717347 · EU 2024-515566-13-00
• No phaseTaking people
  An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

  Where

  Hong Kong

  Age

  18 years and over

  People

  300 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07200375
• Phase 2/3Taking people
  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Where

  Hong Kong

  Age

  18 years and over

  People

  290 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT05139017 · EU 2022-502646-27-00